Expand Hsp90 content

Overview

flowchart TD
    entities_hsp90_protein["Expand Hsp90 content"]
    style entities_hsp90_protein fill:#4fc3f7,stroke:#333,color:#000
    entities_hsp90_prote_0["Structure and Mechanism"]
    entities_hsp90_protein -->|"includes"| entities_hsp90_prote_0
    style entities_hsp90_prote_0 fill:#81c784,stroke:#333,color:#000
    entities_hsp90_prote_1["Normal Function in the Brain"]
    entities_hsp90_protein -->|"includes"| entities_hsp90_prote_1
    style entities_hsp90_prote_1 fill:#ef5350,stroke:#333,color:#000
    entities_hsp90_prote_2["Role in Neurodegenerative Diseases"]
    entities_hsp90_protein -->|"includes"| entities_hsp90_prote_2
    style entities_hsp90_prote_2 fill:#ffd54f,stroke:#333,color:#000
    entities_hsp90_prote_3["Alzheimers Disease"]
    entities_hsp90_protein -->|"includes"| entities_hsp90_prote_3
    style entities_hsp90_prote_3 fill:#ce93d8,stroke:#333,color:#000
    entities_hsp90_prote_4["Parkinsons Disease"]
    entities_hsp90_protein -->|"includes"| entities_hsp90_prote_4
    style entities_hsp90_prote_4 fill:#4fc3f7,stroke:#333,color:#000
    entities_hsp90_prote_5["Huntingtons Disease"]
    entities_hsp90_protein -->|"includes"| entities_hsp90_prote_5
    style entities_hsp90_prote_5 fill:#81c784,stroke:#333,color:#000

Expand Hsp90 Content plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

Heat Shock Protein 90 (Hsp90) is a highly conserved molecular chaperone protein that plays a critical role in protein folding, stability, and quality control in eukaryotic cells. As one of the most abundant cytosolic proteins (comprising 1-2% of total cellular protein), Hsp90 is essential for maintaining proteostasis under both normal and stress conditions[^1]. In the nervous system, Hsp90 performs specialized functions in neuronal protein homeostasis, synaptic plasticity, and response to neurodegenerative stress[^2].

Structure and Mechanism

Hsp90 is a 90 kDa ATP-dependent chaperone that forms a homodimer, with each monomer consisting of three functional domains:

• N-terminal domain (NTD): Contains the ATP-binding pocket and is the target of many Hsp90 inhibitors[^3]

• Middle domain: Serves as the primary interaction surface for client proteins and co-chaperones

• C-terminal domain (CTD): Mediates dimerization and contains theEEVD motif for co-chaperone binding

The Hsp90 chaperone cycle involves ATP binding and hydrolysis, which drives conformational changes that allow client protein folding and transfer to downstream pathways[^4]. Hsp90 works in concert with numerous co-chaperones including Hsp70, Hsp40, p23, and CDC37 to regulate hundreds of client proteins[^5].

Normal Function in the Brain

In neurons, Hsp90 is crucial for:

• Protein folding: Assists in proper folding of nascent polypeptides, particularly membrane proteins and signaling kinases[^6]

• Proteostasis maintenance: Maintains stability of client proteins including kinases, transcription factors, and steroid receptors

• Quality control: Targets misfolded proteins for degradation via the proteasome or autophagy pathways

• Stress response: Rapidly upregulated under cellular stress conditions including oxidative stress, heat shock, and proteotoxic insult

• Synaptic function: Regulates synaptic protein assembly and neuronal excitability

Role in Neurodegenerative Diseases

Hsp90 has emerged as a critical player in the pathogenesis of multiple neurodegenerative diseases[^7]:

Alzheimer’s Disease

In Alzheimer’s disease (AD), Hsp90 client proteins include tau protein and several kinases involved in tau hyperphosphorylation (GSK-3β, CDK5)[^8]. Hsp90 facilitates the propagation of tau pathology by stabilizing pathogenic tau conformers and supporting the templated seeding of tau aggregation[^9]. Additionally, Hsp90 interactions with amyloid-beta precursor protein (APP) and gamma-secretase components influence amyloid-beta production[^10].

Parkinson’s Disease

Alpha-synuclein (α-syn), the primary protein aggregation suspect in Parkinson’s disease (PD), is an Hsp90 client[^11]. Hsp90 stabilizes soluble α-syn oligomers, potentially preventing or promoting aggregation depending on cellular context. Hsp90 also regulates leucine-rich repeat kinase 2 (LRRK2), a PD-associated kinase[^12].

Huntington’s Disease

Mutant huntingtin (mHTT) protein with expanded polyglutamine tracts is an Hsp90 client[^13]. Hsp90 facilitates the folding of mutant proteins, and inhibition of Hsp90 can promote the clearance of mHTT aggregates through autophagy[^14].

Amyotrophic Lateral Sclerosis (ALS)

Several ALS-associated proteins including SOD1, TDP-43, and FUS are Hsp90 clients[^15]. Hsp90 dysfunction contributes to TDP-43 mislocalization and aggregation, a hallmark of ALS pathology[^16].

Client Proteins in Neurodegeneration

Hsp90 regulates numerous client proteins relevant to neurodegenerative diseases:

Therapeutic Targeting

Hsp90 inhibitors represent a promising therapeutic strategy for neurodegenerative diseases[^17]:

Mechanism

Hsp90 inhibitors (e.g., geldanamycin derivatives, purine analogs) bind to the N-terminal ATP-binding pocket, blocking the chaperone cycle and promoting client protein degradation. This leads to:

• Degradation of toxic protein aggregates

• Activation of heat shock factor 1 (HSF1) and upregulation of protective heat shock proteins

• Reduction of pathogenic signaling pathways

Clinical Development

Multiple Hsp90 inhibitors have been evaluated in preclinical models of neurodegenerative diseases:

• Geldanamycin derivatives: 17-DMAG (alvespimycin) and 17-AAG (tanespimycin) show neuroprotective effects in AD and PD models[^18]

• Purine analogs: PU-H71 demonstrates efficacy in tauopathy and α-synucleinopathy models[^19]

• Non-geldanamycin inhibitors: AT13387 and XL888 are being evaluated for CNS penetration

Challenges

Key challenges for Hsp90-targeted therapies include:

• Achieving sufficient brain penetration

• Managing heat shock response activation and potential toxicity

• Achieving selective targeting of pathogenic client proteins

• Balancing chaperone inhibition with preservation of essential neuronal functions

HDAC6 Interaction

Hsp90 function is regulated by post-translational modifications, particularly acetylation. Histone deacetylase 6 (HDAC6) deacetylates Hsp90, modulating its chaperone activity and client protein processing[^20]. This interaction represents a therapeutic target, as HDAC6 inhibitors can restore Hsp90 function and promote clearance of misfolded proteins[^21].

See Also

• HDAC6

• Protein Aggregation

• Molecular Chaperones

• Alzheimer’s Disease

• Parkinson’s Disease

• Huntington’s Disease

• Amyotrophic Lateral Sclerosis

External Links

• HSP90 Alpha (HSPCA) Gene - NCBI

• HSP90AB1 Gene - NCBI

• HSP90AA1 UniProt

• HSP90 Inhibitors in Clinical Trials - ClinicalTrials.gov

Overview

Expand Hsp90 Content plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Expand Hsp90 Content has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

HSP90 expression data from the Allen Brain Atlas:

• Human Brain Atlas - HSP90: Gene expression across cortical regions